Form 4: VolitionRx CMO Gains Shares from RSU Vesting

VolitionRx's Group Chief Marketing Officer, Ann-Louise Batchelor, acquired 33,900 common shares through the partial vesting of restricted stock units.

Summary

• Ann-Louise Batchelor, Group Chief Marketing Officer of VolitionRx Ltd (VNRX), reported an acquisition of 33,900 shares of common stock.
• This acquisition resulted from the vesting of restricted stock units (RSUs) awarded on March 17, 2025, under the Issuer's 2024 Stock Incentive Plan.
• The initial RSU award was for 113,000 units, subject to corporate performance goals and time-based vesting.
• Performance goals were met for 33,900 RSUs, while the remaining 79,100 RSUs did not vest and were cancelled by January 22, 2026.
• The 33,900 vested RSUs are subject to a 3-year time-based vesting schedule, with 11,300 units scheduled to vest on March 17, 2026, 2027, and 2028, respectively.
• Following this transaction, Ms. Batchelor directly beneficially owns 182,072 shares and indirectly owns 29,406 shares through her spouse.

Sentiment

Score: 5

Explanation: While some RSUs vested, indicating partial success in meeting performance goals, a significant portion (70%) did not vest and were cancelled, which presents a mixed signal regarding overall performance achievement.

Positives

• 33,900 restricted stock units (RSUs) vested due to the achievement of certain corporate performance goals, indicating partial success in meeting company objectives.

Negatives

• 79,100 restricted stock units (RSUs) did not vest and were cancelled, representing approximately 70% of the initial 113,000 RSU award.
• The cancellation of a significant portion of RSUs suggests that a substantial number of the corporate performance goals tied to the award were not met.

Future Outlook

The 33,900 vested restricted stock units will convert into common stock in three equal installments of 11,300 units on March 17, 2026, 2027, and 2028, respectively.

Stakeholder Impact

• Shareholders: The future issuance of shares upon vesting will result in minor dilution. The partial achievement of performance goals tied to executive compensation may be viewed with mixed sentiment.
• Management/Employees: The outcome reflects the effectiveness of the compensation structure in incentivizing performance, with a significant portion of the award not vesting.

Next Steps

• Future vesting of 11,300 common shares on March 17, 2026.
• Future vesting of 11,300 common shares on March 17, 2027.
• Future vesting of 11,300 common shares on March 17, 2028.

Key Dates

Recommendation

This Form 4 reports a routine executive compensation event involving the partial vesting of restricted stock units. While 33,900 units vested, indicating some performance goal achievement, a substantial 79,100 units were cancelled, suggesting that a majority of the performance targets were not met. This mixed outcome provides no strong signal for a 'buy' or 'sell' recommendation. Investors should continue to hold and monitor broader company performance and future filings for more comprehensive financial and operational insights.

Keywords

VolitionRx, VNRX, SEC Form 4, Insider Transaction, RSU Vesting, Executive Compensation, Stock Award, Ann-Louise Batchelor